ArticleTranslational lung cancer research2026
Baseline IL-6, IL-8, IFN-ω, and perforin as prognostic biomarkers in immune checkpoint inhibitor-treated metastatic non-small cell lung cancer.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Background: Prognostic serum biomarkers of immune checkpoint inhibitor (ICI) efficacy in non-small cell lung cancer (NSCLC) are sparse. We evaluated baseline cytokines as markers of outcomes in ICI-treated metastatic NSCLC. Methods: Baseline serum cytokines were quantified in 96 patients with metastatic NSCLC receiving ICIs. Separate multivariable models were fit for progression-free survival (PFS) and overall survival (OS), adjusting for clinical covariates. Hazard ratios (HRs) were expressed per doubling in cytokine concentration. Significant cytokines were then incorporated into multivariable Cox models, and model discrimination was assessed using time-dependent area under the curve (AUC). Latent class analysis (LCA) was performed to identify cytokine-defined patient phenotypes associated with survival. Results: Each doubling of interleukin-6 (IL-6) increased the hazard of death by 34% [HR =1.34; 95% confidence interval (CI): 1.13-1.60; P<0.001] and interleukin-8 (IL-8) by 36% (HR =1.36; 95% CI: 1.16-1.59; P<0.001). Conversely, each doubling of interferon-omega (IFN-ω) (HR =0.87; 95% CI: 0.80-0.95; P=0.001) and perforin (HR =0.50; 95% CI: 0.33-0.76; P<0.001) decreased mortality risk. Multivariable cytokine models incorporating IL-6, IL-8, IFN-ω, and perforin achieved time-dependent AUCs >0.70 for PFS and OS. LCA identified two cytokine classes: one enriched for IL-6/IL-8 (poor outcomes) and another enriched for IFN-ω/perforin (favorable outcomes). Conclusions: Higher baseline serum IL-6 and IL-8 concentrations were associated with inferior survival, whereas higher baseline serum IFN-ω and perforin were associated with improved survival in ICI-treated metastatic NSCLC, defining distinct host immune-inflammatory phenotypes with prognostic relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.